The company has signed a long-term global supply agreement with a subsidiary of ITM Isotopen Technologien München, Isotope Technologies Garching to ensure the supply of no-carrier-added Lutetium-177, a key component of Betalutin for R&D, clinical and commercial uses.
ITM, a biotechnology and radiopharmaceutical group of companies in the development and production of radiopharmaceuticals and radionuclides for the targeted treatment of cancers as well as for diagnostics, has been supplying n.c.a. Lutetium-177 to Nordic Nanovector since 2010.
A key milestone
“This global supply agreement is a key milestone in the implementation of our CMC (Chemistry, Manufacturing and Controls) strategy for gaining regulatory approval for Betalutin and its subsequent commercial rollout, as it provides certainty of continued supply of n.c.a. Lutetium-177 during clinical development as well as after launch. The agreement with ITM, alongside other manufacturing supply and development agreements in place with specialist manufacturers at all stages of the manufacturing and supply chain for Betalutin strengthens our confidence in the ability to deliver a reliable and sustainable supply chain in support of the launch of our lead asset,” says Marco Renoldi, Chief Operating Officer at Nordic Nanovector.